Bristol Myers Squibb notified the New Jersey Department of Labor & Workforce Development that it will eliminate 265 positions between December and May 2027 as part of an ongoing restructuring effort tied to its New Jersey operations.
Details of the reduction and where it hits
The company's notice did not provide a precise breakdown of job titles or departments to be cut, but it said the reduction affects some employees based in New Jersey as well as field employees who report to sites in the state. Bristol Myers Squibb maintains a corporate headquarters in Lawrenceville and operates a roughly 650,000-square-foot commercial and research facility there.
“Bristol Myers Squibb is executing its strategy to build for sustainable, long-term growth, and that work is reflected in our performance. We continue to align our resources and organizational structure to meet the demands of a rapidly evolving landscape,”
The company spokesperson added that these efforts are intended to create flexibility to invest in growth opportunities and in its drug development pipeline while delivering long-term value to patients, colleagues and shareholders.
Where this fits in the company’s wider cost-cutting campaign
The latest layoff notice is the most recent move in a broader cost-saving program. In February 2025, Bristol Myers Squibb announced a plan to reduce expenses by $2 billion by the end of that year. Company statements indicate it achieved more than $1 billion in savings in 2025 and remains on track to realize the remaining $1 billion in annual savings by the end of 2027.
Since the initiative began, the company has disclosed more than 1,800 job eliminations in New Jersey tied to restructuring. Earlier this year it notified officials of a separate cut of 206 positions slated between July and December. Less than a year before that, BMS unveiled global plans that included trimming roughly 2,220 jobs and targeting about $1.5 billion in savings through workforce reductions.
Company rationale and reinvestment priorities
Executives say a portion of savings from the restructuring will be redirected toward research and development in areas the company has identified as high priority, including oncology, hematology, fibrosis and cardiovascular disease. The company framed the layoffs as a way to align resources with a shifting commercial and scientific landscape.
- Scope: 265 job eliminations tied to New Jersey sites and reporting lines.
- Timing: Separations scheduled between December and May 2027.
- Facilities: Corporate HQ and large commercial/R&D campus in Lawrenceville.
Local impact and unanswered questions
Large-scale reductions at major employers can ripple through local economies, affecting suppliers, service firms and tax bases. The company’s Lawrenceville campus houses commercial and research operations that contribute to the region’s life-sciences employment pool. The notice did not specify whether the reductions will include research positions tied to ongoing clinical programs or are concentrated in corporate and field operations.
Also unclear from the filing is the mix of involuntary layoffs versus voluntary departures or transfers, and whether affected employees will receive severance, transition assistance, or support for retraining. The state Department of Labor & Workforce Development typically coordinates with employers and local workforce boards when mass layoffs are reported to help deliver services to displaced workers.
How this compares to prior disclosures
| Item | Figure |
|---|---|
| Layoffs disclosed in this notice | 265 |
| Earlier NJ layoffs reported since 2025 | More than 1,800 |
| Global job reduction announced previously | About 2,220 |
| Cost-savings target (2025 initiative) | $2 billion (target) More than $1B saved in 2025; remaining $1B by end of 2027 |
Company spokespeople emphasized that the restructuring is intended to strengthen long-term growth prospects and support investment in key therapeutic areas. For employees and communities tied to Bristol Myers Squibb’s New Jersey operations, however, the immediate concern will be the pace of job losses and the availability of support services to ease transitions.
State officials and local workforce agencies often respond to notices filed under the Worker Adjustment and Retraining Notification (WARN) process by coordinating job-search assistance, unemployment insurance information, and retraining programs. Details about those resources are typically made available after formal notices are filed with the state.
As Bristol Myers Squibb moves forward with its productivity initiative, New Jersey will again watch how decisions by a major employer reshape employment and innovation within the state’s life-sciences sector.
Rohan Iyer is the state correspondent covering business and economic developments for WE NEWS.
